Spyre Therapeutics (SYRE) Stock Price, Quote, News & History | Benzinga

Spyre Therapeutics Inc (SYRE) Stock Price, Quote, News & History

SYRENASDAQ

Trade with Public

Trade with Public

$104.35

-0.59-0.56%

At close: Aug 5, 5:00 PM EST

$103.48

-0.87-0.83%

After Hours: 4:53 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$104.94

Close

$104.35

Volume / Avg.

1.04M / 1.31M

Day Range

$100.88 - $108.14

52 Wk Range

14.51 - 105.25

Market Cap

$8.93B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.53%

Days to Cover

9.03

Recent Spyre Therapeutics Inc News

Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.

Avi Kapoor

Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announcement. Other stocks also down in pre-market.

Avi Kapoor

What's Going On With Spyre Therapeutics Stock On Wednesday?

Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market sentiment for SYRE.

Vandana Singh

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.

Avi Kapoor

Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 million. Other gainers include MGN, VTAK, CUPR, QNRX, CCXI, WEN, BNC, CAST, and ALPS. XCH and TOP were among the losers.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-185.63M

Investing Cash Flow (TTM)

-86.83M

Financing Cash Flow (TTM)

321.15M

Free Cash Flow (TTM)

-185.63M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

48.69M

Analyst Trends and Forecast

9

Apr

2

May

3

Jun

1

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$8.53B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

17.71

Earnings Yield % (TTM)

-2.02%

Earnings Yield % (FWD)

-3.14%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.93

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$97.19M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$104.94

Close

$104.35

Volume / Avg.

1.04M / 1.31M

Day Range

$100.88 - $108.14

52 Wk Range

14.51 - 105.25

Market Cap

$8.93B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

15.53%

Days to Cover

9.03

About

Sector

Health Care

Industry

Biotechnology

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes exten...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Spyre Therapeutics (SYRE) stock?

A

You can purchase shares of Spyre Therapeutics (NASDAQ:SYRE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Spyre Therapeutics (SYRE) competitors?

A

There are no as such competitors for Spyre Therapeutics.

Q

What is the forecast, or price target, for Spyre Therapeutics (SYRE) stock?

A

Spyre Therapeutics has a consensus price target of $99.40.

Q

What is the current price for Spyre Therapeutics (SYRE)?

A

The stock price for Spyre Therapeutics (NASDAQ: SYRE) is $103.48 last updated August 5, 2026 at 4:53 PM EDT.

Q

Does Spyre Therapeutics (SYRE) pay a dividend?

A

There are no upcoming dividends for Spyre Therapeutics.

Q

When is Spyre Therapeutics (NASDAQ:SYRE) reporting earnings?

A

Spyre Therapeutics does not have any upcoming earnings scheduled.

Q

Is Spyre Therapeutics (SYRE) going to split?

A

There is no upcoming split for Spyre Therapeutics.

Q

What sector and industry does Spyre Therapeutics (SYRE) operate in?

A

Spyre Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.